CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Total Current Liabilities

All obligations due within one year.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities falls 32.2% from a year ago

Total current liabilities stood at $34.02M at the end of Q1 FY2026, down 32.2% from a year earlier and down 27.0% from the prior quarter. Over 3 fiscal years it compounded at -32.7% a year.

Context

  • Total current liabilities amounted to 9.5% of total assets at the end of Q1 FY2026, down 41.5 pp from a year earlier.
  • Total current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -32.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$34.02M-27.0% QoQ
Last fiscal yearDec 2025
$46.62M-45.7% YoY
Year agoMar 2025
$50.2M-32.2% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.2%——
1 year-45.7%——
3-year CAGR-32.7%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
46.62M USD
Year-over-year change
-45.7%
4-year CAGR
-12.0%

Total Current Liabilities vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's Mar 2026 total current liabilities of $34.02M is the 8th highest of the 10 companies compared; the peer median is $70.81M.
  • Its year-over-year change of -32.2% is the 8th highest of 10, against a peer median of +17.0%.
  • Total current liabilities amounts to 9.5% of total assets for CTMX, versus a peer median of 23.2%.
CTMX Competitors Peer median
Total Current Liabilities for CTMX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZYMEZymeworks Inc.Sep 2026$161.46M +284.0%-23.8%13.7%
NRIXNurix Therapeutics, Inc.Aug 2026$130.74M +58.8%+7.0%10.9%
MGNXMacroGenics, Inc.Mar 2026$95.94M +73.0%-3.9%44.0%
XNCRXencor, Inc.Jun 2026$81.87M -14.8%+14.5%11.3%
STROSutro Biopharma, Inc.Mar 2026$70.81M -46.8%+4.1%29.3%
ADCTADC Therapeutics S.A.Mar 2026$67.63M +17.0%-5.0%23.2%
CLDXCelldex Therapeutics, Inc.Sep 2026$60.52M +30.2%+39.9%8.4%
CTMXCytomX Therapeutics, Inc.Mar 2026$34.02M -32.2%-32.7%9.5%
ADAGAdagene Inc.Dec 2025$25.17M -34.1%-23.0%32.2%
PYXSPyxis Oncology, Inc.Mar 2026$16.53M +14.6%-12.6%25.7%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) $70.81M+17.0%-3.9%23.2%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents205.53M193.65M17.17M38.05M12.67M
Short-term Investments99.7M0157.34M62.57M124.39M
Net Receivables790K35.99M3.43M3.1M2.01M
Inventory00000
Other Current Assets07.47M5M3.58M4.86M
Total Current Assets310.3M237.1M182.94M107.31M143.92M
Property, Plant & Equipment (Net)25.32M21.02M16.18M10.6M4.7M
Goodwill949K949K949K949K949K
Intangible Assets1.02M875K729K583K438K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.82M944K1M1.09M1.56M
Total Non-current Assets29.11M23.79M18.86M13.23M7.65M
Total Assets339.41M260.89M201.79M120.53M151.57M
Account Payables2.82M2.81M1.46M1.09M1.3M
Short-term Debt00004.24M
Tax Payables00000
Deferred Revenue40.82M121.27M132.27M67.2M26.88M
Other Current Liabilities009.44M05.99M
Total Current Liabilities77.87M152.61M155.91M85.77M46.62M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)243.94M180.06M80.05M26.86M1.59M
Other Non-current Liabilities003.89M4.12M4.35M
Total Non-current Liabilities262M194.03M93.33M35.22M5.94M
Total Liabilities339.87M346.64M249.24M120.99M52.56M
Common Stock1K1K1K1K2K
Retained Earnings(623.56M)(722.88M)(723.45M)(691.58M)(711.95M)
Accumulated OCI(242K)10K95K27K111K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(459K)(85.75M)(47.45M)(456K)99.01M
Total Debt21.67M18.06M13.97M9.39M4.24M
Net Debt(183.86M)(175.59M)(3.2M)(28.67M)(8.43M)

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.